The mission of the Human Immunology Core (HIC) is to provide human immune assays and expertise to facilitate immunoassessment of clinical trials, and specimens and reagents to facilitate basic and translational research that enhances our understanding of the tumor microenvironment and the host immune response. During the previous five years the HIC has supported 25 early stage clinical trials. The HIC facility is directed by Cari June, Professor of Pathology and Laboratory Medicine. Dr. June is recognized for his contributions to basic human immunology and for leadership in translational and therapeutic human cancer immunotherapy. Dr. Jean Boyer serves as Technical Director of the facility. Dr. Boyer is an expert in the assessment of clinical cellular immune responses to vaccines and immunotherapy and oversees an experienced staff. Specifically the staff provides relevant immunologic assays and reagents for basic and clinical research. The HIC services include providing purified primary human blood cell subsets, and annotated specimen handling and storage. The range of services provided by the HIC staff also includes proliferation assays, multinational lymphocyte subset analysis by flow cytometry, as well as a number of assays to assess lymphocyte activation and specificity. Lymphocytes can be assessed by the quantitative and sensitive ELISpot assay, TCR repertoire, or by multiparameter techniques, intracellular cytokine staining and luminex bead array technology. Importantly, the staff works closely with each PI to be sure that the immunological assays are optimally matched to each clinical trial. The specific approach and assays that are applied to each clinical trial are discussed with the PI to most efficiently address the goals of the respective trial. The nature of the current immunological assays requires that an expert staff be available to perform assays and have knowledge of the instrumentation. Finally, the HIC can perform all studies on a pilot research basis, or at the standard of Good Laboratory Practices, as appropriate for the particular needs of the trial. By facilitating the immunoassessment of clinical cancer trials, the HIC supports clinical and translational scientists. By providing access to patient biopsy specimens, the HIC also facilitates research on the tumor microenvironment, thereby supporting the research of basic scientists as well. Over 40 ACC members have used the core in the last year. ACC member usage is 48% of the total core usage. CCSG support represents 21% of the proposed core budget with the remaining funding coming from charge backs and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593274
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$210,169
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Lee, Kyoung Eun; Spata, Michelle; Bayne, Lauren J et al. (2016) Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov 6:256-69

Showing the most recent 10 out of 848 publications